文献速递内脏/肾动脉与血管畸形

口服西罗莫司治疗复杂低流量血管畸形的回顾性研究

Oral sirolimus therapy for patients with complex low-flow vascular malformations.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2025-05-19

结论认为口服西罗莫司在标准治疗不足时临床有效且安全。

要点

  • 口服西罗莫司可使58.2%的复杂低流量血管畸形患者获得部分改善。
  • 最常见不良事件为口腔溃疡(54.5%),仅9.1%患者无任何不良事件。

核心结论

  • 口服西罗莫司治疗在标准治疗不足的复杂低流量血管畸形患者中临床有效且安全。
  • 需要更长期随访的进一步研究来评估口服西罗莫司在低流量血管畸形患者中的应用。

研究设计与样本

  • 单中心回顾性研究,纳入2016年5月1日至2023年4月30日期间标准治疗不足并接受口服西罗莫司的成人低流量血管畸形患者55例(14例综合征型,41例非综合征型),中位年龄41岁(范围23-72岁)。

主要发现

  • 生活质量评分中生理问题、精力/疲劳和疼痛维度改善无统计学意义,焦虑和抑郁评分增加无统计学意义。
  • 2例报告蜂窝织炎发作停止,8例报告畸形相关出血或直肠出血部分或完全减少。
  • 最常见不良事件为口腔溃疡(54.5%)、疲劳(29.1%)、头痛(25.5%)、胃肠道问题(25.5%)和皮疹(12.7%);仅5例(9.1%)未报告任何不良事件;综合征型与非综合征型患者不良事件无显著差异。

关键数值与推荐

  • 口腔溃疡发生率54.5%,疲劳29.1%,头痛25.5%,胃肠道问题25.5%,皮疹12.7%,无不良事件者9.1%。

临床怎么用

  • 对于标准治疗不足的复杂低流量血管畸形成人患者,口服西罗莫司可作为临床有效且安全的治疗选择。
  • 治疗期间需关注口腔溃疡、疲劳、头痛、胃肠道问题和皮疹等不良事件。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The evidence on the efficacy and safety of sirolimus therapy in patients with low-flow vascular malformations (LFVMs) has indicated its potential benefit in extensive and complicated lesions. This study aimed to assess the efficacy and safety of oral sirolimus therapy on complex LFVM patients when standard treatment alone was inadequate. METHODS: This was a retrospective study of all adult patients with diagnosed LFVMs who were treated with oral sirolimus where standard therapy was inadequate in a single specialist center from May 1, 2016, to April 30, 2023. Demographic and clinical data including patient reported responses, visual analogue scores for pain and adverse effects, and quality of life (QoL) scores (Short Form-36) were reviewed. RESULTS: We included 55 LFVM patients (14 with syndromic disease and 41 with nonsyndromic) with a median age of 41 years (range, 23-72 years). While on sirolimus, 32 patients (58.2%) experienced some improvement with a nonsignificant higher percentage of nonsyndromic patients experiencing some improvements (P = .6478). There was a nonsignificant improvement in the quality of life scores for physical problems, energy/fatigue, and pain. There was also a nonsignificant increase in anxiety and depression scores. There was a significant decrease in the lesion size (P = .0004). Two patients reported a cessation of cellulitis episodes, and eight patients reported a partial or complete reduction in bleeding from their malformation or rectal bleeding. The most common side effects reported were mouth ulcers (54.5%), fatigue (29.1%), headache (25.5%), gastrointestinal problems (25.5%), and rash (12.7%); only five patients (9.1%) did not report any side effects. No significant difference was found between the side effects reported by syndromic and nonsyndromic patients. CONCLUSIONS: Oral sirolimus therapy was clinically effective and safe in patients with complex LFVMs when standard therapy alone was inadequate. Further studies with longer follow-up are needed to evaluate oral sirolimus therapy in LFVM patients.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Nisbet R, Pang C, Evans N, et al. Oral sirolimus therapy for patients with complex low-flow vascular malformations. J Vasc Surg Venous Lymphat Disord. 2025. PMID: 40398816. doi:10.1016/j.jvsv.2025.102261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。